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DOI 10.1016/j.immuni.2011.01.011SUMMARY with commonly used adjuvants has not been strongly evidentThe contribution of Toll-like receptor (TLR) signaling
to T cell-dependent (TD) antibody responses was as-
sessed by using mice lacking the TLR signaling
adaptor MyD88 in individual cell types. When
a soluble TLR9 ligand was used as adjuvant for
a protein antigen, MyD88 was required in dendritic
cells but not in B cells to enhance the TD antibody
response, regardless of the inherent immunogenicity
of the antigen. In contrast, a TLR9 ligand contained
within a virus-like particle substantially augmented
the TD germinal center IgG antibody response, and
this augmentation required B cell MyD88. The ability
of B cells to discriminate between antigens based on
the physical form of a TLR ligand probably reflects an
adaptation to facilitate strong antiviral antibody
responses.
INTRODUCTION
Activation of B cells to produce antibodies is of central impor-
tance in defense against infectious agents. B cell activation is
initiated by antigen recognition through the B cell antigen
receptor (BCR) and requires additional activating signals such
as those coming from helper T cells and/or other immune cells
stimulated via innate recognition. Recent attention has focused
on the role of innate recognition by Toll-like receptors (TLRs)
for antibody production (Pasare and Medzhitov, 2005; Gavin
et al., 2006). The ability of TLR ligands to boost antibody
responses in mice is mainly dependent on expression of
MyD88, a key adaptor for the signaling of most TLRs. MyD88-
deficient mice exhibit reduced steady-state amounts of IgG2
isotypes even under specific pathogen-free conditions (Gavin
et al., 2006; Pasare and Medzhitov, 2005) and have been found
to have attenuated antibody responses to some immunizations
(Pasare and Medzhitov, 2005) and to a number of pathogens,
including influenza virus and Streptococcus pneumoniae (Heer
et al., 2007; Khan et al., 2005). Although the importance of
TLRs for antibody responses to protein antigens combined(Gavin et al., 2006), purified TLR agonists are known to act on
their own as effective adjuvants for antibody responses both in
mice and in humans (Bekeredjian-Ding and Jego, 2009; Halperin
et al., 2006; Jennings and Bachmann, 2008).
TLR ligands may act on multiple cell types after immunization.
Stimulation of TLRs on antigen-presenting cells such as
dendritic cells (DCs) is known to induce their maturation and
secretion of cytokines (Reis e Sousa, 2004), which can promote
the activation of helper T cells. B cells also express TLRs such as
TLR4, TLR7, and TLR9 and can respond to TLR agonists in vitro
by proliferating and differentiating into antibody-secreting cells
(Bekeredjian-Ding and Jego, 2009). Indeed, B cell-intrinsic
TLR-MyD88 signaling has been implicated in the anti-RNA and
anti-DNA autoantibody responses in several spontaneous
mouse models of systemic lupus erythematosus (SLE) (Shlom-
chik, 2009). However, in response to immunization that includes
TLR agonists in the adjuvant, whereasMyD88 signaling in B cells
is required for the production of IgG2b and IgG2c isotypes of
T cell-dependent (TD) antibodies in some studies (Pasare and
Medzhitov, 2005; Jegerlehner et al., 2007), complete loss of
MyD88 in mice or selectively in B cells has little effect on anti-
body responses in several other studies (Gavin et al., 2006;
Meyer-Bahlburg et al., 2007). Thus, although it is clear that
TLRs and MyD88 signaling can promote antibody responses,
there is little understanding of the rules governing how MyD88
and TLR signaling contribute to antibody responses in vivo.
It has been proposed that factors such as the nature or immu-
nogenicity of the antigen used may explain the discrepancies
seen in these studies (Lanzavecchia and Sallusto, 2007; Palm
and Medzhitov, 2009). However, another potentially important
variable that has not been carefully investigated is the impact
of the physical form of the TLR agonist. We recently reported
that altering the physical form of a TLR ligand critically affects
the ability of different immune cell types to respond in vivo
(Hou et al., 2008). Here we have presented studies demon-
strating that, depending on the physical context in which a TLR
ligand is presented, MyD88 signaling in either B cells or in DCs
can substantially augment antibody responses to protein anti-
gens combined with TLR ligands. In particular, DC but not
B cell TLRs enhanced the antibody response to soluble protein
antigens mixed with or chemically linked to a TLR ligand. In
contrast, B cell MyD88 greatly enhanced the TD antibodyImmunity 34, 375–384, March 25, 2011 ª2011 Elsevier Inc. 375
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Figure 1. Antibody Responses to TI Antigens in the
B Cell-Myd88–/– Mice
Wild-type and B cell-Myd88/ mice were immunized i.p.
with 20 mg of NP-Ficoll (A) or NP-LPS (B). The titers of anti-
NP IgM and IgG3 were measured by ELISA. The titers of
individual mice (circles on the graph) and geometrical
mean of each mouse group (bar graph) on day 7 are
shown. Similar results were obtained in one (A) and two
(B) additional experiments. **p < 0.01.
Immunity
Role of B Cell TLRs in Antibody Responses to Virusresponse to a virus-like particle antigen that incorporated TLR
ligands or to chemically inactivated influenza virus. Moreover,
a dense array of antigenic epitopes on the viral particle promoted
the ability of TLR signaling in the B cell to enhance the germinal
center response. These results suggest that B cells are hard
wired to respond vigorously to particles with the properties of
many viruses and that this may represent an evolutionary adap-
tation that contributes to immune defense against virus infection.RESULTS
Generation of Mice Lacking MyD88 Selectively in DCs
and B Cells
For these experiments, we took advantage of a recent mouse
model in which specific ablation of the mouse Myd88 gene in
certain cell types can be engineered via Cre-lox technology.
Mice with specific deletion of Myd88 in DCs (DC-Myd88/
mice) were generated by crossing mice with the Myd88fl allele
to mice expressing the recombinase Cre under the control of
the Cd11c promoter (Caton et al., 2007), as has been reported
before (Hou et al., 2008). To generate mice lacking Myd88
specifically in B cells, mice with the Myd88fl allele were crossed
to mice expressing Cre under the control of the murine Cd79a
promoter (Cd79a-Cre, also known as mb1-Cre) (Hobeika et al.,
2006). In these mice, deletion of the Myd88fl allele, measured
by a quantitative polymerase chain reaction (PCR) assay (Hou
et al., 2008), occurred in more than 98% of follicular B cells
and marginal zone B cells in the spleen and of peritoneal B cells
(data not shown). Thesemice had normal numbers ofmature and
immature B cells in the bone marrow and the spleen, except for
a slight reduction in the number of recirculating mature B cells in
the bone marrow (Figure S1A available online). Cell surface
expression of IgM was also very similar to that of control mice
for the various B cell subpopulations (Figure S1A). Moreover,
the lymphoid organs (spleen and LNs) of these mice exhibited
normal cellular composition and structure (data not shown).
The functional and signaling responses to BCR stimulation
were very similar to those of control mice (Figures S1B and
S1C and data not shown). In contrast, B cells isolated from these
mice showed selective defects in response to TLR9 stimulation,
including upregulation of CD86 and proliferation (Figure S1D).
These results demonstrated that the ablation of MyD88 signaling
in B cells had little effect on the development of B cells or on BCR
function in these mice. We refer to these mice here as B cell-
Myd88/ mice.376 Immunity 34, 375–384, March 25, 2011 ª2011 Elsevier Inc.Antibody Responses to T Cell-Independent Antigens
in the B Cell-Myd88–/– Mice
To see whether ablation of Myd88 in B cells affected their func-
tional properties in vivo, we first examined the antibody
responses to T cell-independent (TI) antigens. The prototypical
TI type 2 antigen 4-hydroxy-3-nitrophenylacetyl (NP)-Ficoll,
which activates B cells by extensive crosslinking of multiple
BCRs and hence generates very strong BCR signaling (Mond
et al., 1995), induced comparable amounts of NP-specific IgM
and IgG3 antibodies in the wild-type and B cell-Myd88/ mice
(Figure 1A), consistent with normal BCR function in mice lacking
MyD88 in B cells. In contrast, in response to NP-lipopolysaccha-
ride (LPS), a TI type 1 antigen containing a TLR4 ligand as carrier,
the mice lacking MyD88 selectively in B cells exhibited substan-
tially attenuated NP-specific IgM and IgG3 responses compared
to wild-type mice (Figure 1B). This result agrees with the in vitro
observation that dual recognition by the BCR and a TLR is
required for an optimal antibody response to this type of antigen
(Bekeredjian-Ding and Jego, 2009).Antibody Response to Soluble Protein Antigens Mixed
with a Soluble TLR Ligand
We next examined the role of TLR signaling in particular cell
types for the antibody responses to T cell-dependent (TD)
protein antigens in the presence of a soluble TLR ligand as
adjuvant. Wild-type, Myd88/, B cell-Myd88/, and DC-
Myd88/ mice were immunized intraperitoneally (i.p.) with
ovalbumin (OVA) mixed together with a TLR9 ligand, an oligo-
deoxynucleotide (ODN) containing an unmethylated CpG motif
(hereafter referred to as CpG). Whereas the early IgM response
was not affected in the mice lacking MyD88 in all cells or just in
DCs, the primary and/or secondary IgG1 and IgG2 responses
were greatly reduced in these animals (Figures 2A and 2B).
These results indicate a requirement for DC-intrinsic MyD88
signaling for soluble CpG to activate DCs, which presumably
activate T cells to provide help to B cells. Surprisingly, however,
the B cell-Myd88/ mice exhibited no obvious defect in the
production of OVA-specific IgM or IgG in either the primary
response or in the secondary response after rechallenge with
OVA (Figures 2A and 2B). Similar results were seen when using
other soluble antigens including NP-haptenated chicken
gamma globulin (data not shown). These results demonstrate
that a TLR9 agonist can promote an antibody response to
a protein antigen in a manner that requires DC MyD88 but not
B cell MyD88.
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Figure 2. Antibody Response to OVA Mixed with a Soluble TLR9
Ligand
Wild-type, DC-Myd88/, B cell-Myd88/, or Myd88/ mice were immu-
nized i.p. with 100 mg of OVA mixed with 50 mg of CpG (ODN 1826) and
were rechallenged i.p. with 10 mg of OVA 4 weeks later. Antibody titers of indi-
vidual mice and the geometrical mean of each mouse group in the primary
response (IgM on day 7 and all IgG isotypes on day14) (A) or secondary
response (7 days after rechallenge) (B) are shown. Statistical comparison
was between wild-type mice and the other mouse groups and was calculated
with the Mann-Whitney U-test. Similar results with the same or different doses
of OVA were obtained in four additional experiments. *p < 0.05, **p < 0.01.
Immunity
Role of B Cell TLRs in Antibody Responses to VirusAntibody Response to Soluble Protein Antigens
Physically Linked to a TLR Ligand
To test whether this lack of effect of TLR signaling in B cells may
be due to poor availability of this soluble TLR ligand to the endo-
cytically localized TLRs of the antigen-specific B cells, we next
examined the antibody responses to immunizations with a TLR
agonist that was physically linked to the antigen, because it
has been shown that BCR-mediated endocytosis can deliver
TLR ligands to internal compartments where they can stimulate
TLR9 (Chaturvedi et al., 2008; O’Neill et al., 2009; Eckl-Dorna
and Batista, 2009). To this end, CpG was covalently linked to
OVA, and the resulting conjugate (OVA-CpG) contained on
average 2–4 CpG ODNs per OVA molecule (data not shown).
After immunization of mice with OVA-CpG, the early antigen-
specific IgM response was reduced in the B cell-Myd88/
mice to approximately 10% of the response in wild-type mice
(Figure 3A), a result that was similar to the IgM response to
NP-LPS. These results indicate that efficient recognition of
a soluble TLR ligand after BCR-mediated uptake promoted the
IgM response. However, despite a reduction in the IgM
response, the B cell-Myd88/ mice made primary and
secondary IgG responses that were very similar to those of
wild-type mice (Figures 3A and 3B). Again, the primary and
secondary IgG response to the conjugate was reduced in the
Myd88/ mice and in the DC-Myd88/ mice (Figures 3A and
3B), consistent with a requirement for TLR signaling in DCs to
optimally promote the helper T cell response (Pasare and Medz-
hitov, 2004).To test whether the same principles also applied to other
protein antigens with TLR agonist activity, we next examined
the antibody response to bacterial flagellin, a natural ligand for
TLR5, which is strongly immunogenic compared to OVA. The
primary IgM and IgG responses to flagellin were unaffected in
mice lacking B cell-intrinsic MyD88 signaling (Figure 3C). In
contrast, Myd88/ mice had a strong reduction in both IgM
and IgG responses and similar defects were seen in mice lacking
MyD88 only in DCs (Figure 3C). Thus, the role of MyD88 signaling
in augmenting the antibody response to flagellin was primarily in
DCs. This is in contrast to what was observed in similar experi-
ments utilizing adoptive transfer of Myd88/ B cells into
B cell-deficient mice (Pasare and Medzhitov, 2005). The results
described above, in which mice were immunized with OVA
(a weakly immunogenic antigen) or flagellin (a strongly immuno-
genic antigen), did not support the hypothesis that the inherent
immunogenicity of an antigen affects the requirement for TLR
signaling in B cells for promoting TD antibody responses, but
instead demonstrated that inherent immunogenicity was poorly
predictive of the importance of B cell-intrinsic MyD88 signaling
for the magnitude of the antibody response.
Antibody Response to a Protein Antigen Mixed
with Aggregated TLR Ligands
We previously found that CpG aggregated by the cationic lipid
DOTAP stimulates a greater range of cell types in vivo than
does soluble CpG (Hou et al., 2008). Consequently, immuniza-
tion with OVA together with CpG-DOTAP induced substantially
more antigen-specific IgG than immunization with OVA plus an
equal amount of soluble CpG (Figure S2A). To examine whether
MyD88 signaling in B cells is required for the optimal IgG
response to immunization with this type of aggregated TLR
ligand, B cell-Myd88/ mice were immunized with OVA
together with CpG-DOTAP. Again, B cell-Myd88/ mice ap-
peared to have no defect in their antibody responses, whereas
Myd88/ mice had a large defect (Figures 4A and 4B). Similar
results were obtained when mice were immunized i.p. with
OVA plus LPS, a naturally aggregated ligand of TLR4 (Figure 4C).
These results indicated that MyD88 signaling in B cells is not
essential for the TD antibody responses elicited by this type of
TLR ligand.
Whereas DC-Myd88/ mice had a substantial defect in
producing antibody after immunization with OVA + soluble
CpG, these mice exhibited largely normal antibody responses
to immunization with OVA plus CpG-DOTAP as we reported
before. This response was lost, however, when the DC-specific
deletion of Myd88 was coupled with a deficiency of the type 1
interferon receptor 1 (IFNAR1) (Figure S2B), indicating that the
strong type 1 IFN response to CpG + DOTAP can provide an
alternative to MyD88 signaling in DCs to promote the antibody
response. Similarly, when DCs were acutely depleted via injec-
tion of diphtheria toxin into mice expressing the primate diph-
theria toxin receptor selectively in DCs, the antibody response
was strongly diminished (Figure S2C), proving that DCs were still
required for the antibody response when CpG-DOTAP was used
as adjuvant. These results suggested that the immune-
enhancing effect of aggregating the TLR ligand, and/or any other
adjuvant effects DOTAPmay have, wasmainly through augmen-
tation of the DC-T cell component of the response.Immunity 34, 375–384, March 25, 2011 ª2011 Elsevier Inc. 377
**
**
** ****
** **
**
*
**
*
**
*
**
*
C
A
**
**
**
**
**
**
**
**
**
**
B
OVA-CpG Primary
OVA-CpG Secondary Flagellin Primary
WT
B cell-Myd88-/-
Myd88-/-
DC-Myd88-/-
* p<0.05
** p<0.01
IgM IgG2bIgG1total IgG IgG2c
IgM IgG2bIgG1total IgG IgG2c
IgM IgG2bIgG1total IgG IgG2c
106
103
104
105
101
102
106
103
104
105
101
102
106
103
104
105
101
102
Figure 3. Antibody Response to Protein
AntigensPhysically LinkedwithTLRLigands
Wild-type, DC-Myd88/, B cell-Myd88/, or
Myd88/ mice were immunized i.p. with OVA-
CpG conjugate (containing 50 mg OVA and 32 mg
CpG) and rechallenged i.p. with 10 mg of OVA
4 weeks later (A and B) or were immunized with
25 mg of flagellin (FliC) (C). Shown are the titers of
anti-OVA or anti-flagellin of individual mice and
the geometrical mean of each mouse group in
the primary response (A and C) or secondary
response (B). Immunization with the same
OVA-CpG in two additional experiments and with
a different preparation resulted in similar findings
to (A) and (B). Similar results to (C) were obtained
in an additional experiment. *p < 0.05, **p < 0.01.
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Role of B Cell TLRs in Antibody Responses to VirusAntibody Response toQb Virus-like Particles Containing
TLR Ligands
We next examined the role of TLR signaling in DCs and in B cells
for response to a particulate antigen containing a TLR agonist as
is typical of virus particles. For these experiments, we used the
well-characterized proteinaceous virus-like particles (VLPs)
made by the bacteriophage Qb capsid protein (Jegerlehner
et al., 2007). The self-assembled VLPs contain single-stranded
RNA (ssRNA) that can stimulate RNA-recognizing TLRs such
as TLR7 (hereby referred to as VLP-ssRNA) (Jennings and Bach-
mann, 2008) but cannot directly infect mammalian cells. Tomake
VLPs containing CpG, VLPs were disaggregated into Qb dimers,
which were then purified and assembled with G10 CpG ODNs.
On average, each Qb VLP with CpG incorporated (here referred*
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378 Immunity 34, 375–384, March 25, 2011 ª2011 Elsevier Inc.to as VLP-CpG) contained 60–80 CpG
ODNs together with its 180 Qb subunits
(Senti et al., 2009). Immunization of mice
with VLP-CpG induced potent Qb-specific IgM and IgG antibody responses. The IgG response
was largely dependent on ab T cells, as shown by the fact that
it was greatly reduced (to 1%) in mice lacking T cell receptor
a chain (Figure S3A). This result is consistent with our previous
report with mice largely deficient in CD4+ T cells because of
genetic deficiency of major histocompatibility complex (MHC)
class II molecules (Gatto et al., 2004). The amount of Qb-specific
IgM produced was similar after immunization with empty VLPs
mixed with equal molar amounts of soluble CpG or immunization
with VLPs that had physical inclusion of CpG in VLPs. In contrast,
the IgG response was greatly enhanced by physical incorpora-
tion of CpG in the VLPs, and it was strongly directed to the
IgG2c and IgG2b isotypes (Figure 5A). These and previous
results (Jegerlehner et al., 2007) indicate that incorporation ofFigure 4. Antibody Response to a Protein
Antigen Mixed with Aggregated TLR
Ligands
Mice were immunized i.p. with 100 mg of OVA
mixed with 25 mg of DOTAP-aggregated CpG
(ODN1826) and rechallenged i.p. with 10 mg of
OVA 4 weeks later (A and B) or were immunized
with 100 mg of OVA mixed with 25 mg of LPS (C).
Shown are the titers of antigen-specific antibody
of individual mice and the geometrical mean of
each mouse group in the primary response
(A and C) or secondary response (B). Similar
results were obtained in two (A and B) and one
(C) additional experiments. *p < 0.05, **p < 0.01.
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Figure 5. Antibody Response to Qb VLP Containing CpG ODNs
(A) C57BL/6mice were immunized i.p. with 50 mg of VLP-CpG or 37.5 mg empty VLPmixed with 12.5 mg CpG (ODN 1826). Shown are the titers of antigen-specific
antibody of individual mice (circle for VLPmixed with CpG, and cross for VLP-CpG) and the geometrical mean of eachmouse group (horizontal bar) in the primary
responses. Similar results were obtained in one additional experiment.
(B and C) Mice of specified genotype were immunized i.p. with 50 mg of VLP-CpG.
(B) Shown are the titers of anti-Qb of individual mice and the geometrical mean of each mouse group in the primary responses. Similar results were obtained on
day 21 and day 28.
(C) Shown are the numbers of anti-Qb-secreting cells (ASCs) in the spleen on day 11 after immunization (mean+SD of three mice in each group). Statistical
comparisons were calculated with Student’s t test. Similar differences were also seen on day 21 after immunization.
(D) Wild-type and B cell-Myd88/mice were immunized i.p. with 37.5 mg of empty VLP mixed together with 12.5 mg of CpG (ODN1826). Shown are the titers of
antigen-specific antibody of individual mice and the geometrical mean of each mouse group in the primary responses on day 14 after immunization.
(E) Mice of the specified genotype were immunized i.p. with 50 mg of VLP-CpG. Representative flow cytometry plots of isotype-switched Qb-specific B cells in the
spleen on day 11 after immunization (three mice in each group). Most Qb-specific B cells also stained positive for GL-7 (data not shown). Similar results were
obtained on day 21 after immunization.
*p < 0.05, **p < 0.01.
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Role of B Cell TLRs in Antibody Responses to Virusa TLR9 agonist within the Qb VLPs strongly promoted a TD anti-
body response.
The immune-stimulating effect of CpG incorporated inside
VLPs depended on MyD88 signaling as expected, because the
IgG response to VLP was almost completely ablated in
Myd88/ mice (Figure 5B). Mice lacking MyD88 in DCs ex-
hibited as strong a VLP-specific IgG response as did wild-type
mice (Figure 5B), whereas depletion of DCs again completely
ablated the response (Figure S3B), presumably reflecting a role
for DCs in the activation of helper T cells specific for peptidesderived from the VLPs. Whereas in the case of CpG + DOTAP
immunization, type 1 interferons were apparently responsible
for inducing DC maturation, that was not the case with VLPs,
because deficiency of type 1 IFN signaling combined with dele-
tion of Myd88 selectively in DCs did not diminish the IgG
response to the VLP-CpG (data not shown).
Remarkably, B cell-Myd88/ mice had a substantially atten-
uated IgG response, which manifested as dramatically
decreased IgG2c and IgG2b titers combined with a relatively
moderate elevation of IgG1 titers (Figure 5B). In agreementImmunity 34, 375–384, March 25, 2011 ª2011 Elsevier Inc. 379
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Figure 6. Antibody Response to a Protein Antigen
Coupled to VLPs
Wild-type and B cell-Myd88/ mice were immunized i.p.
with 50 mg of VLP-ssRNA (A) or FD1-VLP-ssRNA conju-
gates (B and C). Shown are the primary response titers
of anti-Qb (A and C) and anti-Fel d1 (FD) (B) of individual
mice and the geometrical mean of each mouse group.
Similar results were obtained in one additional experiment.
*p < 0.05, **p < 0.01.
Immunity
Role of B Cell TLRs in Antibody Responses to Viruswith the serum titers of anti-Qb IgG, the B cell-Myd88/ mice
had substantially fewer anti-Qb-secreting cells in the spleen after
immunization (Figure 5C). Immunization of Cd79a-Cre mice
(without Myd88fl allele) induced similar amounts of IgG as in
C57BL/6 mice, suggesting that the defect observed in the
B cell-Myd88/ mice is not caused by any nonspecific Cre-
mediated recombination or difference in genetic background
(Figure S3C). Additionally, no dramatic defect in IgG response
was observed in the B cell-Myd88/ mice after immunization
with empty VLPs (lacking internal ssRNA or CpG) mixed together
with CpG (Figure 5D), indicating that incorporation of a TLR
ligand in the VLP is required for a TLR signal in B cells to promote
the TD antibody response.When the antibody responses to VLP-
CpG and VLPs mixed with CpG in B cell-Myd88/ mice were
compared, similar titers of total IgG as well as of the different
IgG isotypes were found (Figures 5B and 5D), consistent with
the conclusion that activation of MyD88-dependent signaling in
B cells was largely responsible for the boosting effect on the
TD antibody response by CpG within VLPs.
Immunization with VLP-CpG has been shown to induce
a strong and prolonged germinal center (GC) response (Gatto
et al., 2004). To examine whether the GC response was affected
inmice lackingMyD88 signaling in B cells, the phenotypes of iso-
type-switchedQb-specific B cells in the spleenwere analyzed by
flow cytometry after immunization. Eleven days after immuniza-
tion, isotype-switched Qb-specific B cells had expanded
dramatically in wild-type mice, and themajority of these cells ex-
hibited a GC phenotype (Figure 5E), whereas these responses
were severely defective in the B cell-Myd88/ mice. These
results demonstrate that intrinsic MyD88 signaling is required
for B cells to make an optimal GC response after immunization
with a virus-like particulate antigen containing a TLR9 ligand.
When we used the Qb VLPs that contained ssRNA, we found
that the IgG anti-Qb response was also greatly diminished in
the B cell-Myd88/ mice (Figure 6A), indicating that a TLR7
ligand can also engage B cell TLRs and promote the TD antibody
response to VLPs.380 Immunity 34, 375–384, March 25, 2011 ª2011 Elsevier Inc.Antibody Response to a Protein Antigen
Coupled to VLPs
BCR-mediated delivery of nucleic acid TLR
ligands to an endocytic compartment, where
TLR7 and TLR9 signal (Barton and Kagan,
2009), is probably essential for VLPs containing
these ligands to induce a strong TD anti-VLP
response. Other properties of VLPs, however,
may also be required for them to synergize
with B cell TLR signaling to enhance the TD anti-
body response, because CpG conjugated toa soluble protein antigen did not exhibit a requirement for
B cell MyD88 (Figure 3A). The antigen of the VLPs exhibits
a repeating array of epitopes, which are likely to induce espe-
cially strong BCR signaling and could be of different immunoge-
nicity from the other soluble antigens because of its bacterio-
phage origin. To test how these factors might influence the
antibody response and the B cell TLR contribution to it, we
examined the antibody responses to a covalent conjugate of
the Qb ssRNA VLP and a soluble protein antigen, Fel d1, a cat
allergen (the conjugate is hereby referred to as FD1-VLP-ssRNA)
(Schmitz et al., 2009). The Fel d1 epitopes did not appear to have
any unique properties compared to other soluble antigens we
have tested, because immunization with soluble Fel d1 mixed
with CpG induced a TD antibody response that was not depen-
dent on MyD88 signaling in B cells (data not shown). The Fel d1-
conjugated particles exhibited new epitopes supplied by the Fel
d1 protein (50 Fel d1 per VLP containing 180 Qb monomers)
and probably had a reduced density of the Qb protein epitopes
exposed for recognition by the BCR.
Immunization with FD1-VLP-ssRNA induced antibody
responses to both Fel d1 and Qb epitopes. Remarkably, the
IgG response to Fel d1 epitopes was substantially enhanced
(10-fold) in wild-type mice compared to B cell-Myd88/
mice (Figure 6B), indicating that the ability of B cell TLR signaling
to enhance the TD antibody response was not limited to Qb
epitopes. The Fel d1-modified VLPs retained a strong IgG
response to Qb epitopes that was highly dependent on B cell
MyD88 (Figure 6C). However, the difference between the anti-
Qb IgG response of the wild-type and B cell-Myd88/mice ap-
peared to be somewhat decreased compared with immunization
with un-derivatized VLP-ssRNA (Figures 6A and 6C), suggesting
that the degree of multimerization of the VLP epitope determines
the extent to which B cell TLR signaling boosts the TD antibody
response. Consistent with this hypothesis, when mice were
immunized with a CpG VLP conjugate that contained a lower
density of Fel d1 (9–18 Fel d1 per CpG-containing VLP), the Fel
d1-specific IgG antibody response of wild-type mice was only
**
*
*
*
*
**
*
WT
B cell-Myd88-/-
Myd88-/-
DC-Myd88-/-
IgM IgG2bIgG1total IgG IgG2c
106
103
104
105
* p<0.05
** p<0.01
Figure 7. Antibody Responses to Immunization with Inactivated
H1N1 Influenza Virus
Mice were immunized i.p. with 10 mg of formalin-inactivated H1N1 PR/8 influ-
enza virus. Shown are the titers of antigen-specific antibody of individual
mice and the geometricalmean of eachmouse group in the primary responses.
Similar resultswere obtained in one additional experiment. *p < 0.05, **p < 0.01.
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Qb-specific response ranged from 20- to 30-fold more
(Figure S4).
Antibody Response to Virons of H1N1 Influenza Virus
Lastly, to examine whether B cell-intrinsic MyD88 signaling is
also required for antibody responses to a native virus particle,
we challenged mice with inactivated influenza virus, which
contains single-stranded RNA genomic segments that can acti-
vate TLR7 (Diebold et al., 2004), but unlike Qb VLPs is an envel-
oped virus. After immunization, a strong anti-influenza IgG
response was rapidly induced in the wild-type mice. Similar to
what was seen in response to Qb VLP, the anti-influenza total
IgG and IgG2 responses were greater (3- to 10-fold) in wild-
type mice than in Myd88/ mice and there was no reduction
in DC-Myd88/ mice (Figure 7). Strikingly, B cell-Myd88/
mice exhibited a defective response similar to that in the
Myd88/ mice (Figure 7), indicating that B cell-intrinsic
MyD88 signaling contributes importantly to the magnitude of
the anti-influenza virus humoral response.
DISCUSSION
In this study, we obtained evidence that TLR ligands can engage
TLR signaling in both B cells and DCs resulting in augmentation
of TD antibody responses and that a dominant determinant of
the cellular pathway engaged and the extent of augmentation
is the physical context in which the TLR ligand is presented to
the immune system. In particular, TLR-MyD88 signaling in DCs
but not in B cells was required to enhance the IgG response to
a soluble protein antigen either mixed with a soluble TLR9 ligand
or chemically conjugated to it. In contrast, VLPs that contained
a TLR9 or TLR7 ligand or inactivated influenza virus were able
to engage TLR and MyD88 signaling within the antigen-specific
B cells to strongly enhance a primary germinal center response.
The selective utilization of B cell TLR signaling by TLR7 or
TLR9 ligands contained within VLPs but not by soluble TLR
ligand or by TLR ligand chemically coupled to soluble antigen
for the enhancement of T cell-dependent IgG production is the
most remarkable finding of this study. TLR ligands are potent
activators of murine B cells in vitro (Bekeredjian-Ding and
Jego, 2009; Shlomchik, 2009), and therefore, it has been
presumed that TLRs in B cells play an important role in
promoting antibody responses in vivo. Indeed, Pasare andMedzhitov (2005) provided evidence that B cell TLRs were
responsible for enhancing the magnitude of the TD antibody
response. Subsequent studies have either provided evidence
for a role for TLRs in promoting antibody responses or failed to
see a role, depending on the circumstance examined, illustrating
that much needs to be learned about the role of TLRs in antibody
responses. We examined antibody responses to several soluble
protein antigens with different apparent immunogenicity mixed
with a TLR ligand as adjuvant and found that deletion of
Myd88 selectively in B cells did not decrease the magnitude of
the IgG responses. In addition, when we used a TLR ligand
that had been physically linked to an antigen to increase delivery
of the TLR ligand to B cell TLRs, we observed a contribution of
TLR signaling in B cells only to the early IgM response but not
to the TD IgG response. Instead, in all these circumstances,
we found that MyD88 signaling in DCs accounted for most of
the effect of TLR stimulation, suggesting that signals from helper
T cells are sufficient to promote a strong B cell response,
provided that the CD4 T cells are activated by TLR-stimulated
DCs. Similarly, MyD88 signaling in DCs was recently shown to
be important for the IgA response to intranasal immunization
(Bessa et al., 2009). Our results argue against the hypothesis
that proteins of low immunogenicity enable TLRs to boost the
response, whereas highly immunogenic proteins, such as
haptenated proteins, do not (Palm andMedzhitov, 2009). Rather,
regardless of the strength of the TD antibody response to
a soluble protein antigen, it was MyD88 in DCs, not B cells,
that boosted the response.
In contrast to what was seen with soluble protein antigens and
soluble TLR ligands, we found that similar TLR ligands contained
within VLPs had the unique ability to engage TLR signaling in
B cells to strongly enhance TD IgG production. The magnitude
of the IgG response to VLPs was typically approximately 30-
fold greater in wild-type mice compared to mice with deletion of
Myd88 selectively in B cells. The low IgG response in B cell-
Myd88/mice was similar to what was seen upon immunization
of wild-type mice with VLPs depleted of nucleic acid and mixed
with free CpG ODNs, and this latter response was not affected
by deletion of Myd88 in B cells. Thus, incorporation of the TLR
ligand within the VLP was necessary for enabling B cell TLR
signaling to boost the IgG response. This ability of VLPs to induce
a robust IgG response by engaging B cell TLR signaling was
apropertyof thephysical formof theVLPs, not the inherent immu-
nogenicity of the protein epitopes exposed on the particle. For
example, a weakly immunogenic protein, the cat allegen Fel d1,
when used as a soluble antigen mixed with CpG ODN, behaved
like the other soluble protein antigens tested in that the IgG
response was decreased by deletion of Myd88 in DCs but was
unaffected by deletion of Myd88 in B cells. In contrast, when
Fel d1wasconjugated to theVLPscontainingnucleic acid ligands
for TLRs, these VLPs induced a robust anti-Fel d1 IgG response
that benefited substantially from MyD88 expression in B cells.
Earlier studies designed to distinguish the contribution of
B cell MyD88 from the contribution of MyD88 in other cell types
(Pasare and Medzhitov, 2005) used adoptive transfer of MyD88-
deficient B cells into mMTmice, which have deletion of exons en-
coding the transmembrane domain of IgM and therefore are
genetically defective in B cell development. Such mice are
known to have substantial alterations in the structure of theirImmunity 34, 375–384, March 25, 2011 ª2011 Elsevier Inc. 381
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pressing lymphotoxin-b (Chaplin, 2002). These mice may also
have elevated amounts of the cytokine B cell-activating factor
belonging to the TNF family (BAFF) resulting from B cell lympho-
penia, and either of these changes may alter the timing or other
aspects of the B cell response. Thus, it is possible that the acti-
vation of CD4 helper T cells is suboptimal in this experimental
system. In this respect, the use of Cre-lox technology for deletion
ofMyd88 selectively in B cells in situ, as was done in the exper-
iments presented here, has obvious advantages.
Themechanism by which virus particles engage B cell TLR7 or
TLR9 signaling to enhance the TD IgG response deserves further
investigation, but the results presented here provide some
insights. The major component of the TD response that was
stimulated was the germinal center response, which is respon-
sible for producing high-affinity antibody, long-lived plasma
cells, and memory B cells (King et al., 2008). Moreover, the
magnitude of the enhancement seen in wild-type mice
compared to B cell-Myd88/ mice was consistently affected
by the epitope density on the VLPs: unmanipulated VLP-ssRNA
or VLP-CpG exhibited the strongest enhancement by B cell
MyD88, whereas low-density Fel d1 conjugation resulted in
a lower enhancement of the anti-Fel d1 IgG response compared
to the anti-Qb IgG response. When Fel d1 was conjugated onto
the VLPs at a higher density, then a larger enhancement of the
anti-Fel d1 IgG response was seen. Thus, there was a consistent
trend toward greater enhancement by B cell MyD88 when the
epitope density on the surface of the VLP was higher, indicating
that greater engagement of BCRs and presumably stronger BCR
signaling enabled B cell TLR enhancement of the response.
Another feature of VLPs that may enable B cell MyD88 to
enhance the antibody response may be their likely ability to
induce strong TLR signaling by virtue of the amount of TLR7 or
TLR9 ligand contained within a single VLP. For example, the
VLP-CpG contained an estimated 60–80ODNs per virus particle.
Additionally, it is possible that soluble and particulate antigens
are processed differently in B cells after being taken up by
BCRs; the latter may be more efficiently trafficked to the location
where nucleic acid-recognizing TLRs encounter their cognate
ligands. Similar cell biological contributions to the nature of
TLR responses have been described in plasmacytoid DCs
(Honda et al., 2005).
It is striking that particles with two of the characteristic
features of most virus particles and lacking in many other types
of particles, namely high density of particular epitopes and
internal ligands for TLR7 or TLR9, uniquely engage this mecha-
nism to strongly enhance the germinal center IgG response.
Given the well-established function of neutralizing antibodies
for defense against many viruses (Zinkernagel et al., 2001), this
property of B cells is likely to be an evolutionary advantageous
regulatory mechanism to promote rapid and robust production
of high-affinity antibodies to protect against virus infection.
This phenomenon may also explain the common observations
that immunization with attenuated or inactivated complete path-
ogens typically induces stronger antibody responses than immu-
nization with the components of pathogen mixed with a TLR
ligand or with other commonly used adjuvants. For example,
Geeraedts et al. (2008) have reported that vaccination with inac-
tivated whole H5N1 influenza virus induced better protective382 Immunity 34, 375–384, March 25, 2011 ª2011 Elsevier Inc.antibody responses than vaccination with split virus or a viral
subunit vaccine. Our results indicate that activation of MyD88
signaling in B cells by a TLR ligand presented in the physical
context of a virus particle may be an important mechanism to
account for the superior immunogenicity of this type of antigen.
The ability of VLPs to promote vigorous IgG responses by TLR
signaling in B cells is intriguing in light of previous work impli-
cating B cell TLR signaling in spontaneous production of anti-
nuclear antibodies and anti-RNA antibodies, the autoantibodies
characteristic of the human autoimmune disease systemic lupus
erythematosus (Marshak-Rothstein and Rifkin, 2007). Based on
our results, we propose that the autoantigens in these casesmay
be exposed to B cells in the form of apoptotic blebs, because
many antibodies of this type will bind to those structures (Cline
and Radic, 2004). Apoptotic blebs resemble VLPs in their partic-
ulate nature and in their inclusion of a substantial amount of
ligands for TLR7 and/or TLR9. Interestingly, the role of MyD88,
TLR7, and TLR9 in augumenting spontaneous or induced auto-
antibody production in a few mouse models has been attributed
to promoting extrafollicular antibody responses (Shlomchik,
2009), whereas we found that it was the germinal center
response that was promoted by VLPs and TLR signaling in
B cells. Therefore, it would be worth examining the contribution
of the germinal center B cell response to spontaneous anti-DNA
or anti-ribonucleoparticle autoantibody production in other
mouse models of SLE.
In summary, our experiments clearly demonstrate that TLRs of
both DCs andB cells can augment antibody responses, depend-
ing on the physical nature of the antigen. In particular, immuniza-
tions with soluble protein antigens mixed with or conjugated to
TLR ligands as the major adjuvant demonstrated a requirement
for TLR signaling in DCs but not B cells for a high-titer IgG
response to soluble protein antigens, whereas immunization
with VLPs containing TLR ligands within them had a requirement
for B cell MyD88 for a robust IgG response to the repeating
epitopes of the VLP. Pathogens such as viruses contain nucleic
acid that serves as ligands for TLRs such as TLR7 and TLR9, but
it was not previously appreciated that such particles are espe-
cially able to engage B cell TLRs to enhance TD antibody
responses. Thus, the results presented here suggest that B cells
are hard-wired to respond strongly to virus particles and use
their TLRs for this purpose, a property that probably has consid-
erable advantage for defense against viral infection. These
insights may be useful in the development of more effective
vaccines.
EXPERIMENTAL PROCEDURES
Mice
B6 (000664; C57BL/6J) and BoyJ (002014; B6.SJL-Ptprca Pepcb/BoyJ) mice
were from Jackson Laboratory. The Myd88fl (B6.129P2-Myd88tm1Defr) and
theMyd88fl/fl Cd11c-Cre (DC-Myd88/) mice have previously been described
(Hou et al., 2008) and were backcrossed to a B6 background for at least nine
generations for this study. Cd79a-Cre transgenic mice on a C57BL/6 back-
ground (eight generations) were originally from M. Reth (Hobeika et al.,
2006) and were crossed to mice with the Myd88fl allele to generate Myd88fl/fl
Cd79a-Cre mice.Myd88/ mice were originally from S. Akira (Osaka Univer-
sity, Osaka, Japan) (Adachi et al., 1998) and were backcrossed to B6 for 10
generations in our colony. Tcra/ mice (Mombaerts et al., 1992) were ob-
tained from M. Hermiston (UCSF). CD11c-Diphtheria Toxin Receptor (DTR)
(004509; B6.FVB-Tg (Itgax-DTR/EGFP) 57Lan/J) mice were originally
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to a B6 background for ten generations in our colony.
All experimental mice were used at 8–16 weeks of age and were sex-
matched and age-matched (within 2 weeks) within experiments. All animals
were housed in a specific-pathogen-free animal facility at UCSF under condi-
tions that meet institutional animal care and use committee (IACUC) and NIH
guidelines.Reagents
Chicken ovalbumin fraction VI (OVA) was purchased from Sigma-Aldrich, and
endotoxin-free OVA was obtained by Triton X-114 treatment as described
(Aida and Pabst, 1990). NP-Ficoll (NP-AECM-FICOLL) and NP-LPS were
purchased from Biosearch Technologies. NP-conjugated bovine serum
albumin (NP10-BSA) was conjugated as described (Hannum et al., 2000).
Salmonella typhimurium flagellin (FliC) was purified from a fljB fliC+ strain
(TH4778) kindly provided by K. Hughes (University of Utah, UT), according
to a protocol (Ibrahim et al., 1985) modified by K.D. Smith (University of Wash-
ington, WA). Diphtheria toxin was purchased from Biomol research laborato-
ries. Influenza A/PR/8/34 (H1N1) virus was purchased from Charles River
and inactivated with 1/4000 of stock formaldehyde solution (37%w/w contain-
ing 10%–15% methanol) according to a protocol reported before (Katz and
Webster, 1989).
Type B CpG ODN 1826 (50-TCCATGACGTTCCTGACGTT-30) was
purchased from Integrated DNA Technologies (IDT), and type B CpG ODN
1018 (50-TGACTGTGAACGTTCGAGATGA-30) was provided by Dynavax, Inc.
Type A CpG G10 (50-GGGGGGGGGGGACGATCGTCGGGGGGGGGG-30)
with a phosphodiester backbone used for incorporation into VLPs was
provided by BioSpring GmbH. All other ODNs contained a phosphorothioate
backbone. Dioleoyloxy-trimethylammonium-propane-methylsulfate (DOTAP)
was obtained from Roche and was complexed with CpG as described previ-
ously (Hou et al., 2008). Ultra pure LPS (E. coli 0111:B4) were purchased
from Invivogen.
Conjugation of OVA with 1018 CpG followed a modified protocol as previ-
ously described for conjugation of ragweed allergen Amb a 1 (Tighe et al.,
2000). In brief, OVA was activated by reaction with sulfosuccinimidyl 4-N-
maleimidomethyl cyclohexane-1-carboxylate (sulfo-SMCC) in 100 mM
NaPO4, 150 mMNaCl, 1 mM EDTA (pH 7.5) buffer. The activated OVA then re-
acted with a sulfhydryl derivative of the ODN 1018 to give a mixture of conju-
gates with 1–7 CpG ODNs attached. Free OVA and CpG ODN were removed
from the conjugate by pooling gel filtration (Superdex 200 10/300 GL [GE
Healthcare Life Sciences]) fractions, based on analysis by SDS-PAGE.
VLPs derived from the bacteriophage Qb were expressed in E. coli strain
JM109 harboring the expression plasmid pQ10 and purified as previously
described (Cielens et al., 2000). Self-assembled VLPs contained 300 mg of
E. coli-derived ssRNA per milligram of Qb VLPs. ssRNA-free VLPs (VLP)
were obtained by digestion with RNase A, and VLPs containing CpG were ob-
tained by in vitro packaging VLPs with CpG ODN G10, both as described in
detail elsewhere (Jegerlehner et al., 2007). In brief, for the latter procedure,
Qb VLPs were disassembled in vitro and Qb coat proteins purified. Purified
coat proteins were then mixed with aggregated G10 ODN and allowed to
assemble to VLPs. Free G10 ODN was removed from the assembled VLPs
containing G10 ODN inside the particles. One milligram of packaged Qb con-
tained 250–300 mg of CpG ODN. Recombinant Fel d1 was generated by
expression of plasmid pET-42T 3 Fel d1-15as-HC in E. coli strain BL21
(DE3), and FD1-VLP conjugate was obtained by coupling of Fel d1 to VLP,
as previously described (Schmitz et al., 2009). For staining Qb VLP-specific
B cells, Qb VLPs were labeled with fluorescent dye Alexa 647 with a kit from
Invitrogen.Immunization and Serum Collection
Mice were immunized by i.p. injection of antigen and TLR ligand in PBS. For
primary antibody responses, sera were collected on day 7 for the measure-
ment of IgM or IgG3 and on day 14 (and in some experiments also on days
21 and 28) for the measurement of total IgG, IgG1, IgG2b, and IgG2c. For
secondary responses to OVA immunization, mice were injected i.p. with 10
mg of endotoxin-free OVA on day 28 after the primary immunization, and
sera were collected 7 days later.Enzyme-Linked Immunosorbent Assay and ELISPOTs
To determine the amount of antigen-specific immunoglobulin isotypes in
serum, 96-well ELISA plates (BD Falcon) were coated overnight with antigens
with the following conditions: 5 mg/ml NP10-BSA, 10 mg/ml OVA, or 0.5 mg/ml
inactivated H1N1 virus in PBS, 1 mg/ml Flagellin, 2 mg/ml VLP-ssRNA, or
5 mg/ml recombinant Fel d1 in 0.1 M carbonate buffer (pH 9.5). Prediluted
sera were loaded onto the plate and then were serial diluted. Antigen-specific
IgM, total IgG, and IgG isotypes were detected with horseradish peroxidase
(HRP)-conjugated anti-mouse IgM, total IgG (Bethyl Laboratories), IgG1,
IgG2b, IgG2c, or IgG3 reagents (Southern Biotech). The HRP substrate
3,30,5,50-tetramethylbenzidine (TMB) was purchased from Vector Laborato-
ries. Antibody titers were determined as the reciprocal of the dilution that
gave an optical density value (450–570 nm wavelength) that was more than
ten times of the standard deviation above the mean value of the negative
control wells. When no signal was detected, a value of one third of the recip-
rocal of the initial dilution factor was assigned.
To detect anti-Qb-secreting cells (ASCs) in the spleen, 96-well filter plates
(Millipore) were coated overnight with 2 mg/ml of VLP-ssRNA in carbonate
buffer. Three-fold dilution of splenocytes from immunized mice were added
in the filter plates starting at 1 3 106/well in RPMI1640 medium with 10%
FBS and incubated at 37C for 5 hr. The plates were then washed and incu-
bated with HRP-conjugated anti-mouse IgM, total IgG, IgG1, IgG2b, or
IgG2c reagents before addition of the substrate 3-amino-9-ethyl carbazole
(AEC). The substrate reaction was stopped by rinsing plates with tap water.
Plates were dried overnight and ELISPOTs were counted in each well.
Flow Cytometry
For detection of Qb-specific B cells, single cell suspensions of splenocytes
from immunized mice were blocked with antibody against CD16 and CD32
(BD PharMingen) and then stained with fluorescent antibodies in ice-cold
flow cytometry buffer (PBS supplemented with 2 mM EDTA, 1% heat-inacti-
vated FBS, and 0.02% sodium azide). The antibodies included FITC-labeled
anti-IgM, anti-IgD, anti-CD4, anti-CD8, anti-CD11b, anti-Gr-1, and PE-labeled
anti-CD19, PE-Cy7-labeled anti-CD95, and Alexa Fluro 647-labeled Qb VLPs.
All fluorochrome-conjugated monoclonal antibodies were purchased from BD
PharMingen or eBioscience. All data were collected on a LSRII flow cytometer
(Becton Dickinson) and were analyzed with FlowJo software (TreeStar).
Statistical Analysis
Statistical significance was calculated with the unpaired Student’s t test or the
Mann-Whitney U-test. All p values of 0.05 or less were considered significant.
SUPPLEMENTAL INFORMATION
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